Learn more about the #FRONTIERstudy: https://bit.ly/3UifcLi #recurrentGBM #TheraSphereGBM #Y90 Caution: Investigational Device. Limited by Federal (or US) law to investigational use only. Not available for sale. TheraSphere is not indicated for GBM, and is being studied for such in the FRONTIER clinical trial.
Go Behind The Bench of Lenox Hill Neurosurgery’s FRONTIER clinical trial, sponsored by Boston Scientific Peripheral Interventions. 🔬🧬 The aim of this study is to assess the safety and feasibility of the intra-arterial delivery of TheraSphere™ GBM Y-90 Glass Microspheres in patients with recurrent glioblastoma. Lenox Hill Hospital’s Chief of Neuroendovascular Surgery, Dr. Yafell Serulle, MD, PhD, Interventional Radiologist, Dr. Jonathan Weinstein, and Senior Clinical Research Project Manager, Sanskruti (Sana) Bokil, BS, MS, share how they combine their respective expertise to facilitate this trial and the importance of offering patients treatment at every stage of this disease. Click the link for more information about the FRONTIER study or to contact our Clinical Research Team about enrolling in one of our clinical trials. 🧠 Caution: Investigational Device. Limited by Federal (or US) law to investigational use only. Not available for sale. TheraSphere is not indicated for GBM, and is being studied for such in the FRONTIER clinical trial. https://lnkd.in/eU_uvUB4 #lenoxhillneurosurgery #lenoxhillhospital #lenoxhill #northwellhealth #northwelllife #northwellcancerinstitute #bostonscientific #glioblastomaawarenessday #glioblastomaawareness #glioblastomaresearch #braintumorresearch #braincancerresearch #neurosurgery #neurosurgeon #madeforthis #raisinghealth #igreels #instagramreels #reels #fyp
Leitender Oberarzt Interventionelle Radiologie und Neuroradiologie bei Klinikum Hochsauerland
5moVery interesting adaptation of SIRT in GBM treatment. In 1956 there was the first attempt of intrathecal chemotherapy which did not work very well in the last decades a lot of studies tried to work on direct arterial delivery of Chemos with or without blood brain barrier disruption. In the last years some colleagues tried to do use Bevacizumab as arterial infusion in small studies in recurrent GBM. Survival rates 0 and PFS are low up to 9 months. Let's hope this works well.